About: Antibody Responses to Influenza A/H1N1pdm09 Virus After Pandemic and Seasonal Influenza Vaccination in Healthcare Workers: A 5-Year Follow-up Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antibody Responses to Influenza A/H1N1pdm09 Virus After Pandemic and Seasonal Influenza Vaccination in Healthcare Workers: A 5-Year Follow-up Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antibody Responses to Influenza A/H1N1pdm09 Virus After Pandemic and Seasonal Influenza Vaccination in Healthcare Workers: A 5-Year Follow-up Study
Creator	Zhou, Fan Cox, Rebecca Jul-Larsen, Åsne Madsen, Anders Nøstbakken, Jane Skrede, Steinar Trieu, Mai-Chi Saevik, Marianne
Source	PMC
abstract	BACKGROUND: The 2009 influenza pandemic was caused by the A/H1N1pdm09 virus, which was subsequently included in the seasonal vaccine, up to 2016/2017, as the A/H1N1 strain. This provided a unique opportunity to investigate the antibody response to H1N1pdm09 over time. METHODS: Healthcare workers (HCWs) were immunized with the AS03-adjuvanted H1N1pdm09 vaccine in 2009 (N = 250), and subsequently vaccinated with seasonal vaccines containing H1N1pdm09 for 4 seasons (repeated group), <4 seasons (occasional group), or no seasons (single group). Blood samples were collected pre and at 21 days and 3, 6, and 12 months after each vaccination, or annually (pre-season) from 2010 in the single group. The H1N1pdm09-specific antibodies were measured by the hemagglutination inhibition (HI) assay. RESULTS: Pandemic vaccination robustly induced HI antibodies that persisted above the 50% protective threshold (HI titers ≥ 40) over 12 months post-vaccination. Previous seasonal vaccination and the duration of adverse events after the pandemic vaccination influenced the decision to vaccinate in subsequent seasons. During 2010/2011–2013/2014, antibodies were boosted after each seasonal vaccination, although no significant difference was observed between the repeated and occasional groups. In the single group without seasonal vaccination, 32% of HCWs seroconverted (≥4-fold increase in HI titers) during the 4 subsequent years, most of whom had HI titers <40 prior to seroconversion. When excluding these seroconverted HCWs, HI titers gradually declined from 12 to 60 months post–pandemic vaccination. CONCLUSIONS: Pandemic vaccination elicited durable antibodies, supporting the incorporation of adjuvant. Our findings support the current recommendation of annual influenza vaccination in HCWs. CLINICAL TRIALS REGISTRATION: NCT01003288.
has issue date	2019-02-01(xsd:dateTime)
bibo:doi	10.1093/cid/ciy487
bibo:pmid	29893797
has license	cc-by
sha1sum (hex)	c4951616b68bf6f7bf039c472c769bc9346a435c
schema:url	https://doi.org/10.1093/cid/ciy487
resource representing a document's title	Antibody Responses to Influenza A/H1N1pdm09 Virus After Pandemic and Seasonal Influenza Vaccination in Healthcare Workers: A 5-Year Follow-up Study
has PubMed Central identifier	PMC6336911
has PubMed identifier	29893797
schema:publication	Clin Infect Dis
resource representing a document's body	covid:c4951616b68bf6f7bf039c472c769bc9346a435c#body_text
is schema:about of	named entity 'Influenza' named entity 'VACCINE' named entity 'caused' named entity 'virus' named entity 'Pandemic' named entity 'Study' named entity 'vaccine' named entity 'Antibody' named entity 'Influenza Vaccination' named entity 'Influenza' named entity 'hemagglutination inhibition' named entity 'hemagglutination inhibition' named entity 'pandemic vaccine' named entity 'antibodies' named entity 'infection' named entity 'vaccination' named entity 'AEs' named entity 'AS03' named entity 'hemagglutination inhibition' named entity 'vaccination' named entity 'antibodies' named entity 'AS03' named entity 'demographic factors' named entity '21 days' named entity 'influenza vaccines' named entity 'pandemics' named entity 'antibodies' named entity 'influenza vaccination' named entity 'vaccination' named entity 'hemagglutinating' named entity 'vaccination' named entity 'antibodies' named entity 'antibodies' named entity 'red blood cells' named entity 'non-parametric' named entity 'Norwegian Medicines Agency' named entity 'vaccination' named entity 'influenza-like illness' named entity 'vaccine' named entity 'vaccination' named entity 'adjuvanted' named entity 'AS03' named entity 'vaccination' named entity 'adjuvanted' named entity 'vaccination' named entity 'informed consent' named entity 'seasonal influenza' named entity 'A/H1N1' named entity 'viruses' named entity 'A/H3N2' named entity 'hemagglutination inhibition' named entity 'vaccination' named entity 'protective antibodies' named entity 'vaccination' named entity 'H1N1pdm09' named entity 'AEs' named entity 'immunization' named entity 'long-term' named entity 'antibody' named entity 'infection' named entity 'CHMP' named entity 'vaccination' named entity 'T-cells' named entity 'hemagglutination inhibition' named entity 'seroconversion' named entity 'AS03' named entity 'humoral responses' named entity 'AS03' named entity 'red blood cells' named entity 'headache' named entity 'hemagglutination inhibition' named entity 'influenza infection' named entity 'statistically significant' named entity 'subclinical infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software